QCLSNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Q/C TECHNOLOGIES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.50−0.04 (-7.10%)
Close on Oct 19, 2026
- Market cap
- $4.12M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
9.0%
1M of 8M shares
Institutional holders
21
6 new, 2 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
1 buys · 0 sales
Net bought $5.52K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| PharmaCyte Biotech, Inc. | 8,475,368 | 74.00% | 13D (active) amendment | Nov 14, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of QCLS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Quinn Opportunity Partners LLC | 123,024 | 1.50% | $479.79K | −88,366 | 0.02% |
| Vanguard Capital Management LLC | 115,031 | 1.40% | $448.62K | +77,520 | 0.00% |
| Jane Street Group, LLC | 87,241 | 1.07% | $340.24K | −38,947 | 0.00% |
| Geode Capital Management, LLC | 70,682 | 0.86% | $275.66K | +23,292 | 0.00% |
| UBS Group AG | 58,894 | 0.72% | $229.69K | −19,095 | 0.00% |
| Balyasny Asset Management L.P. | 57,692 | 0.70% | $225.00K | New | 0.00% |
| Hrt Financial LP | 50,373 | 0.62% | $196 | +27,969 | 0.00% |
| ADAR1 Capital Management, LLC | 50,000 | 0.61% | $195.00K | – | 0.01% |
| Vanguard Fiduciary Trust Co | 43,053 | 0.53% | $167.91K | +27,498 | 0.00% |
| State Street Corp | 25,305 | 0.31% | $98.69K | +12,400 | 0.00% |
| Dimensional Fund Advisors LP | 19,058 | 0.23% | $74.33K | – | 0.00% |
| Northern Trust Corp | 17,997 | 0.22% | $70.19K | New | 0.00% |
| Peak6 LLC | 12,778 | 0.16% | $49.83K | New | 0.00% |
| Pin Oak Investment Advisors Inc | 3,500 | 0.04% | $14 | – | 0.01% |
| Tower Research Capital LLC (TRC) | 1,043 | 0.01% | $4.07K | −550 | 0.00% |
| Barclays PLC | 950 | 0.01% | $3.71K | New | 0.00% |
| SBI Securities Co., Ltd. | 100 | 0.00% | $390 | New | 0.00% |
| BlackRock, Inc. | 19 | 0.00% | $74 | – | 0.00% |
| Caitong International Asset Management Co., Ltd | 9 | 0.00% | $35 | New | 0.00% |
| Jones Financial Companies Lllp | 2 | 0.00% | $7 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 21 | 1M | 9.0% | 6 / 5 | 4 / 2 | 0M | 0M |
| Q1 2026 | 18 | 1M | 7.7% | 7 / 5 | 1 / 7 | 0M | 0M |
| Q4 2025 | 19 | 1M | 9.2% | 10 / 2 | 1 / 2 | 1M | 0M |
| Q3 2025 | 11 | 0M | 0.2% | 11 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of QCLS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 115,031 | 1.40% | $448.62K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 23,353 | 0.29% | $102.05K | 0.00% | May 31, 2026 |
| U.S. Small Cap Portfolio | 13,189 | 0.16% | $34.42K | 0.00% | Jul 31, 2026 |
| Fidelity Series Total Market Index Fund | 6,046 | 0.07% | $26.42K | 0.00% | May 31, 2026 |
| Dimensional U.S. Small Cap ETF | 5,569 | 0.07% | $14.54K | 0.00% | Jul 31, 2026 |
| Fidelity Total Market Index Fund | 5,239 | 0.06% | $22.89K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 2,941 | 0.04% | $12.85K | 0.00% | May 31, 2026 |
| Dimensional US Core Equity 1 ETF | 300 | 0.00% | $783 | 0.00% | Jul 31, 2026 |
| Total Stock Market Index Trust | 194 | 0.00% | $757 | 0.00% | Jun 30, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -2,400 | -0.03% | -$9.36K | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Joshua Silverman | Executive Chairman, Director | 262,191 | 3.20% | Apr 15, 2026 |
| Mitchell Glass | Chief Medical Officer, Director | 12,500 | 0.15% | Apr 15, 2026 |
| Yossef Ehrlichman | Chief Technology Officer | – | – | Sep 22, 2026 |
| Charles Todd Fagan | Chief Financial Officer | – | – | Aug 17, 2026 |
| Ian Thomas Rhodes | Interim CFO | – | – | Apr 18, 2025 |
| Chelsea Sierra Voss | Director | 301,455 | 3.68% | May 14, 2026 |
| Stephen Friscia | Director | 25,000 | 0.31% | Apr 15, 2026 |
| Billy Joe White | Director | 25,024 | 0.31% | Apr 15, 2026 |
| Bruce Bernstein | Director | 25,023 | 0.31% | Apr 15, 2026 |
| PharmaCyte Biotech, Inc. | 10% owner | – | – | Nov 18, 2025 |
| Gary M. Rauch | – | 12,500 | 0.15% | Nov 14, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Joshua Silverman Executive Chairman, Director | Apr 13, 2026 | Award | +162,162 | – | – | 262,191 |
| Chelsea Sierra Voss Director | Mar 30, 2026 | Buy | +1,753 | $3.15 | $5.52K | 61,555 |
| Chelsea Sierra Voss Director | Jan 16, 2026 | Award | +212,500 | – | – | 214,900 |
| Chelsea Sierra Voss Director | Jan 16, 2026 | Award | +25,000 | – | – | 239,900 |
| Billy Joe White Director | Nov 14, 2025 | Award | +22,839 | – | – | 25,024 |
| Mitchell Glass Director, Chief Medical Off. | Nov 14, 2025 | Award | +11,420 | – | – | 12,500 |
| Stephen Friscia Director | Nov 14, 2025 | Award | +22,839 | – | – | 25,000 |
| Joshua Silverman Executive Chairman, Director | Nov 14, 2025 | Award | +91,356 | – | – | 100,029 |
| Bruce Bernstein Director | Nov 14, 2025 | Award | +25,000 | – | – | 25,000 |
| Gary M. Rauch – | Nov 14, 2025 | Award | +11,420 | – | – | 12,500 |
| Mitchell Glass Director, Chief Medical Off. | Oct 3, 2025 | Award | +1,080 | – | – | 1,080 |
| Joshua Silverman Executive Chairman, Director | Oct 3, 2025 | Award | +8,644 | – | – | 8,673 |
| Stephen Friscia Director | Oct 3, 2025 | Award | +2,161 | – | – | 2,161 |
| Gary M. Rauch – | Oct 3, 2025 | Award | +1,080 | – | – | 1,080 |
| Billy Joe White Director | Oct 3, 2025 | Award | +2,161 | – | – | 2,185 |
| Paul Rivard Chief Legal Officer | Aug 24, 2023 | Buy | +150,000 | $1.11 | $166.50K | 400,000 |
| Paul Rivard Chief Legal Officer | Aug 17, 2023 | Buy | +25,000 | $1.12 | $28.00K | 250,000 |
| Paul Rivard EVP of Operations, GC | Dec 8, 2022 | Buy | +10,000 | $1.53 | $15.30K | 225,000 |
| Joshua Silverman Director | Nov 26, 2021 | Buy | +5,000 | $7.55 | $37.75K | 88,775 |
| Joshua Silverman Director | Nov 24, 2021 | Buy | +6,734 | $6.30 | $42.42K | 80,509 |
| Joshua Silverman Director | Nov 24, 2021 | Buy | +3,266 | $7.09 | $23.16K | 83,775 |
| Paul Rivard EVP of Operations, GC | Nov 23, 2021 | Buy | +15,000 | $6.03 | $90.45K | 215,000 |
| Christopher C. Schreiber Director | Apr 16, 2021 | Tax withholding | −46,113 | $4.94 | $227.80K | 88,238 |
| Christopher C. Schreiber Director | Apr 16, 2021 | Option exercise | +131,750 | – | – | 134,351 |
| Christopher C. Chapman JR President, Chief Med. Officer, Director | Apr 16, 2021 | Award | +96,475 | – | – | 96,475 |
| Robert C. Schroeder Director | Apr 16, 2021 | Tax withholding | −14,694 | $4.94 | $72.59K | 29,236 |
| Robert C. Schroeder Director | Apr 16, 2021 | Option exercise | +43,930 | – | – | 43,930 |
| Billy Joe White Director | Apr 16, 2021 | Tax withholding | −38,325 | $4.94 | $189.33K | 71,175 |
| Billy Joe White Director | Apr 16, 2021 | Option exercise | +109,500 | – | – | 112,101 |
| Joshua Silverman Director | Apr 16, 2021 | Option exercise | +109,500 | – | – | 112,101 |
| Joshua Silverman Director | Apr 16, 2021 | Tax withholding | −38,325 | $4.94 | $189.33K | 71,175 |
| Sander Gerber 10% owner | Feb 28, 2020 | Sale | −638 | $2.81 | $1.79K | 240,305 |
| Bay Capital Management LP Hudson 10% owner | Feb 27, 2020 | Sale | −15,300 | $2.72 | $41.62K | 240,943 |
| Bay Capital Management LP Hudson 10% owner | Feb 25, 2020 | Sale | −13,000 | $2.92 | $37.96K | 256,243 |
| Joshua Silverman Director | Jan 1, 2020 | Option exercise | +5,201 | – | – | 5,201 |
| Christopher C. Schreiber Executive Chairman, Director | Jan 1, 2020 | Option exercise | +5,201 | – | – | 5,201 |
| Billy Joe White Director | Jan 1, 2020 | Option exercise | +5,201 | – | – | 5,201 |
| Bay Capital Management LP Hudson 10% owner | Dec 20, 2019 | Buy | +8,000 | $3.02 | $24.16K | 269,243 |
| Bay Capital Management LP Hudson 10% owner | Dec 19, 2019 | Buy | +2,700 | $3.08 | $8.32K | 261,243 |
| Bay Capital Management LP Hudson 10% owner | Dec 18, 2019 | Buy | +7,500 | $3.07 | $23.03K | 258,043 |
| Bay Capital Management LP Hudson 10% owner | Dec 17, 2019 | Buy | +3,000 | $3.03 | $9.09K | 251,043 |
| Bay Capital Management LP Hudson 10% owner | Dec 16, 2019 | Buy | +5,000 | $3.07 | $15.35K | 248,043 |
| Bay Capital Management LP Hudson 10% owner | Dec 13, 2019 | Buy | +6,000 | $3.02 | $18.12K | 243,043 |
| Bay Capital Management LP Hudson 10% owner | Dec 12, 2019 | Buy | +20,600 | $2.98 | $61.39K | 237,043 |
| Bay Capital Management LP Hudson 10% owner | Dec 11, 2019 | Buy | +6,019 | $3.05 | $18.36K | 216,443 |
| Bay Capital Management LP Hudson 10% owner | Dec 11, 2019 | Buy | +26,406 | $3.10 | $81.86K | 210,424 |
| Bay Capital Management LP Hudson 10% owner | Dec 10, 2019 | Buy | +30,000 | $2.97 | $89.10K | 184,018 |
| Bay Capital Management LP Hudson 10% owner | Dec 9, 2019 | Buy | +19,353 | $2.96 | $57.28K | 104,018 |
| Bay Capital Management LP Hudson 10% owner | Dec 9, 2019 | Buy | +50,000 | $2.99 | $149.50K | 154,018 |
| Howard Yeaton CEO, CFO | Oct 2, 2019 | Award | +3,750 | $0.42 | $1.58K | 45,000 |
| Howard Yeaton CEO, CFO | Aug 30, 2019 | Award | +3,750 | $0.43 | $1.61K | 41,250 |
| Howard Yeaton CEO, CFO | Jul 31, 2019 | Award | +3,750 | $0.42 | $1.58K | 37,500 |
| Howard Yeaton CEO, CFO | Jun 28, 2019 | Award | +3,750 | $0.45 | $1.69K | 33,750 |
| Howard Yeaton CEO, CFO | May 24, 2019 | Award | +7,500 | $0.65 | $4.88K | 30,000 |
| Howard Yeaton CEO, CFO | Mar 29, 2019 | Award | +15,000 | $0.97 | $14.55K | 22,500 |
| Howard Yeaton CEO, CFO | Dec 28, 2018 | Award | +7,500 | $1.27 | $9.53K | 7,500 |
| John J. Gormally Chief Executive Officer, Director | Oct 17, 2017 | Award | +150,000 | $0.88 | $132.00K | 180,000 |
| Gary M. Rauch VP - Finance, Treasurer | Oct 17, 2017 | Award | +36,277 | $0.88 | $31.92K | 63,777 |
| John J. Gormally Chief Executive Officer, Director | Oct 17, 2017 | Gift | +150,000 | $0.88 | $132.00K | 180,000 |
| Brandon Thomas Knox Director | Sep 2, 2016 | Gift | −13,750 | – | – | 124,326 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.